--- title: "Sinopharm Group Co. Ltd.'s (HKG:1099) Low P/E No Reason For Excitement" description: "Sinopharm Group Co. Ltd. (HKG:1099) has a low P/E ratio of 8.4x, indicating potential investor caution due to declining earnings. The company's EPS fell by 14% last year and 11% over three years, lead" type: "news" locale: "en" url: "https://longbridge.com/en/news/276085410.md" published_at: "2026-02-17T00:56:45.000Z" --- # Sinopharm Group Co. Ltd.'s (HKG:1099) Low P/E No Reason For Excitement > Sinopharm Group Co. Ltd. (HKG:1099) has a low P/E ratio of 8.4x, indicating potential investor caution due to declining earnings. The company's EPS fell by 14% last year and 11% over three years, leading to a forecasted growth of only 14% next year, below the market's 20%. This suggests that investors are not optimistic about future earnings, resulting in a low P/E. Analysts believe the share price may not rise significantly in the near future, and there is one warning sign to consider before investing. With a price-to-earnings (or "P/E") ratio of 8.4x **Sinopharm Group Co. Ltd.** (HKG:1099) may be sending bullish signals at the moment, given that almost half of all companies in Hong Kong have P/E ratios greater than 13x and even P/E's higher than 26x are not unusual. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/E. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Sinopharm Group could be doing better as its earnings have been going backwards lately while most other companies have been seeing positive earnings growth. The P/E is probably low because investors think this poor earnings performance isn't going to get any better. If this is the case, then existing shareholders will probably struggle to get excited about the future direction of the share price. Check out our latest analysis for Sinopharm Group Want the full picture on analyst estimates for the company? Then our **free** report on Sinopharm Group will help you uncover what's on the horizon. ## Is There Any Growth For Sinopharm Group? The only time you'd be truly comfortable seeing a P/E as low as Sinopharm Group's is when the company's growth is on track to lag the market. Taking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 14%. This means it has also seen a slide in earnings over the longer-term as EPS is down 11% in total over the last three years. So unfortunately, we have to acknowledge that the company has not done a great job of growing earnings over that time. Turning to the outlook, the next year should generate growth of 14% as estimated by the analysts watching the company. With the market predicted to deliver 20% growth , the company is positioned for a weaker earnings result. With this information, we can see why Sinopharm Group is trading at a P/E lower than the market. Apparently many shareholders weren't comfortable holding on while the company is potentially eyeing a less prosperous future. ## The Final Word Using the price-to-earnings ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects. We've established that Sinopharm Group maintains its low P/E on the weakness of its forecast growth being lower than the wider market, as expected. At this stage investors feel the potential for an improvement in earnings isn't great enough to justify a higher P/E ratio. It's hard to see the share price rising strongly in the near future under these circumstances. Before you settle on your opinion, we've discovered **1 warning sign for Sinopharm Group** that you should be aware of. Of course, **you might find a fantastic investment by looking at a few good candidates.** So take a peek at this **free** list of companies with a strong growth track record, trading on a low P/E. ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [600511.CN - SINOPHARM(CNCM LTD)](https://longbridge.com/en/quote/600511.CN.md) - [516500.CN - ChinaAMC CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516500.CN.md) - [516820.CN - Ping An CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/516820.CN.md) - [159615.CN - China Southern Hang Seng Biotech ETF(QDII)](https://longbridge.com/en/quote/159615.CN.md) - [159892.CN - ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)](https://longbridge.com/en/quote/159892.CN.md) - [589720.CN - Guotai SSE STAR Brand Name Drug ETF](https://longbridge.com/en/quote/589720.CN.md) - [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md) - [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md) - [513700.CN - Penghua CSI HK Connect Health Care Composite ETF](https://longbridge.com/en/quote/513700.CN.md) - [000028.CN - Sinopharm Accord](https://longbridge.com/en/quote/000028.CN.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) | | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/en/news/276024005.md) | | Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/en/news/276016059.md) | | Niowave and Novartis enter global actinium-225 Supply Agreement to advance next-generation cancer therapies | Niowave and Novartis enter global actinium-225 Supply Agreement to advance next-generation cancer therapies | [Link](https://longbridge.com/en/news/275604614.md) | | WuXi XDC Launches Cash Offer to Acquire All Remaining Shares of BioDlink | WuXi XDC Cayman Inc. has launched a voluntary conditional cash offer to acquire all remaining shares of BioDlink not alr | [Link](https://longbridge.com/en/news/275670240.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.